SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+7.28%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$1.27B
AUM Growth
+$1.27B
(+1.3%)
Cap. Flow
-$19.9M
Cap. Flow
% of AUM
-1.56%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
15
New
1
Increased
4
Reduced
1
Closed
5
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$43.4M |
| 2 |
Alkermes
ALKS
|
$41.4M |
| 3 |
Gilead Sciences
GILD
|
$18.9M |
| 4 |
Innoviva
INVA
|
$3.34M |
| 5 |
Mersana Therapeutics
MRSN
|
$2.77M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $407M | 31.99% | 13,213,000 +1,343,000 | +11% | +$41.4M |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $214M | 16.8% | 16,390,000 | – | – |
|
|
3
Gilead Sciences
GILD
$140B
| $207M | 16.27% | 2,967,300 +269,900 | +10% | +$18.9M |
|
4
Biogen
BIIB
$19.4B
| $182M | 14.28% | 643,000 | – | – |
|
|
5
Innoviva
INVA
$1.29B
| $111M | 8.68% | 6,614,000 +200,000 | +3% | +$3.34M |
|
6
BioCryst Pharmaceuticals
BCRX
$1.74B
| $56.4M | 4.43% | 3,926,700 -334,300 | -8% | -$4.8M |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $43.4M | 3.4% | +8,500,000 | New | +$43.4M |
|
|
8
Mersana Therapeutics
MRSN
$36.5M
| $40.5M | 3.18% | 4,299,297 +293,697 | +7% | +$2.77M |
|
9
Vor Biopharma
VOR
$250M
| $11.1M | 0.87% | 707,010 | – | – |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $1.28M | 0.1% | 1,851,851 | – | – |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| – | – | -1,000 | Closed | -$177K |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – | -1,000 | Closed | -$161K |
|
|
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – | -950 | Closed | -$18K |
|
|
SRSAW
14
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
| – | – | -3,333,333 | Closed | -$5M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| – | – | -650,440 | Closed | -$119M |
|